'Young blood' treatments to stop aging, disease are a 'significant public health concern': FDA

Canada News News

'Young blood' treatments to stop aging, disease are a 'significant public health concern': FDA
Canada Latest News,Canada Headlines
  • 📰 ABC
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 51%

'Young blood' treatments to stop aging, disease are a 'significant public health concern,' FDA says.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

ABC /  🏆 471. in US

Canada Latest News, Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA discourages people against 'young blood' infusions, which make unproven claims to reverse agingFDA discourages people against 'young blood' infusions, which make unproven claims to reverse agingThe FDA is advising against 'young blood' infusions, in which people are infused with plasma from young donors. It warns consumers that clinics are making unproven claims that the treatment can reverse aging.
Read more »

FDA warns against using young blood as medical treatmentFDA warns against using young blood as medical treatmentThe US Food and Drug Administration warned against using plasma infusions from young blood donors to ward off the effects of normal aging as well as other more serious conditions.
Read more »

'Young blood' company Ambrosia halts patient treatments after FDA warning'Young blood' company Ambrosia halts patient treatments after FDA warningThe FDA warned consumers against infusions of plasma from young donors, saying there is no evidence that they slow aging or memory loss, and can be dangerous.
Read more »

Ketamine-like depression treatment on track for FDA approvalKetamine-like depression treatment on track for FDA approvalA ketamine-like drug for treatment-resistant depression was backed by a US Food and Drug Administration advisory committee on Tuesday. If it is then approved by the FDA, the drug -- called esketamine -- may provide a new option for patients with major depressive disorder who have tried at least two other antidepressants without success.
Read more »



Render Time: 2025-03-05 07:11:02